Marc Michel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7096028/publications.pdf

Version: 2024-02-01

49 papers 6,049 citations

186265
28
h-index

206112 48 g-index

52 all docs 52 docs citations

52 times ranked 6239 citing authors

#	Article	IF	CITATIONS
1	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
2	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	5.2	593
3	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, The, 2020, 369, m1844.	6.0	355
4	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	5.7	267
5	Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19. Blood, 2020, 136, 2290-2295.	1.4	251
6	Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 2008, 112, 999-1004.	1.4	227
7	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood, 2009, 114, 3167-3172.	1.4	216
8	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematology,the, 2019, 6, e48-e57.	4.6	195
9	B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. Journal of Clinical Investigation, 2013, 123, 432-442.	8.2	154
10	Autoimmune Thrombocytopenic Purpura and Common Variable Immunodeficiency. Medicine (United) Tj ETQq0	0 0 rgBT /0 1.8	Overlock 10 Ti
11	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 2014, 124, 3228-3236.	1.4	142
12	Efficacy and safety of rituximab in common variable immunodeficiencyâ€essociated immune cytopenias: a retrospective multicentre study on 33 patients. British Journal of Haematology, 2011, 155, 498-508.	2.5	125
13	Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a singleâ€center experience with 60 patients. American Journal of Hematology, 2014, 89, E150-5.	4.1	111
14	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	14.3	107
15	Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Review of Hematology, 2011, 4, 607-618.	2.2	103
16	Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases. American Journal of Hematology, 2009, 84, 153-157.	4.1	90
17	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	4.1	84
18	Efficacy and safety of rituximab for systemic lupus erythematosusâ€associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. American Journal of Hematology, 2018, 93, 424-429.	4.1	56

#	Article	IF	CITATIONS
19	Longâ€term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITPâ€ritux. American Journal of Hematology, 2019, 94, 1314-1324.	4.1	55
20	Evans' Syndrome: From Diagnosis to Treatment. Journal of Clinical Medicine, 2020, 9, 3851.	2.4	50
21	Platelet autoantibodies and lupus-associated thrombocytopenia. British Journal of Haematology, 2002, 119, 354-358.	2.5	49
22	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Scientific Reports, 2022, 12, 7140.	3.3	45
23	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood, 2020, 136, 3056-3061.	1.4	42
24	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immunity, 2022, 55, 1096-1104.e4.	14.3	42
25	Hydroxychloroquine is a good secondâ€line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. American Journal of Hematology, 2014, 89, 194-198.	4.1	40
26	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity, 2015, 62, 22-30.	6.5	40
27	Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. Science Translational Medicine, 2021, 13, .	12.4	40
28	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology, 2018, 57, 1432-1438.	1.9	38
29	Bortezomib and dexamethasone, an original approach for treating multiâ€refractory warm autoimmune haemolytic anaemia. British Journal of Haematology, 2019, 187, 124-128.	2.5	29
30	Benefits of rituximab as a secondâ€line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British Journal of Haematology, 2017, 177, 751-758.	2.5	24
31	Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. Haematologica, 2020, 105, 2694-2697.	3.5	23
32	Evans syndrome in adults: an observational multicenter study. Blood Advances, 2021, 5, 5468-5478.	5.2	21
33	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	4.1	20
34	Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. Haematologica, 2021, 106, 3198-3201.	3.5	20
35	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica, 2022, 107, 1698-1702.	3.5	18
36	High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. Journal of Clinical Investigation, 2022, 132, .	8.2	13

#	Article	IF	CITATIONS
37	De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. Blood, 2022, 139, 2561-2565.	1.4	12
38	Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. Blood Advances, 2021, 5, 1617-1626.	5. 2	11
39	Epidemiology of autoimmune hemolytic anemia: A nationwide populationâ€based study in <scp>F</scp> rance. American Journal of Hematology, 2021, 96, E291-E293.	4.1	10
40	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. Blood, 2019, 134, LBA-2-LBA-2.	1.4	9
41	Autologous ¹¹¹ Indiumâ€oxinateâ€labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptorâ€agonists. British Journal of Haematology, 2019, 186, e44-e47.	2.5	8
42	Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study. Blood, 2021, 138, 349-349.	1.4	6
43	Adult Evans' Syndrome. Hematology/Oncology Clinics of North America, 2022, 36, 381-392.	2.2	6
44	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. Blood, 2020, 136, 24-25.	1.4	3
45	Impact of Pregnancy On the Course of Immune Thrombocytopenic Purpura: An Observational Study On 44 Cases Blood, 2009, 114, 1320-1320.	1.4	2
46	Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia: A Retrospective Cohort Study. Blood, 2015, 126, 3483-3483.	1.4	2
47	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	1.4	1
48	Characteristics and Outcome of Adults with Severe Autoimmune Hemolytic Anemia Admitted in Intensive Care Unit: Results from a Large French Observational Study. Blood, 2021, 138, 930-930.	1.4	1
49	Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study. Blood, 2019, 134, 2358-2358.	1.4	0